RxDoctor Payments Data

Amr Mohsen, MD

Interventional Cardiology · Loma Linda, CANPI 1932363132

Payments from drug & device makers

$84,288in general payments, 2019–2025

Across 320 payments — averaging $263.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$24K
  • Edwards Lifesciences$21K
  • Medtronic$17K
  • Boston Scientific$17K
  • Cardiovascular Systems Inc.$3K
  • Philips North America LLC$1K
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$10,76513%
  • Speaking & faculty fees$5,0006%
  • Grants$45,50054%
  • Travel & lodging$10,39112%
  • Food & beverage$12,63315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,288 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$180,861
Medicare patients
320
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$17,550
Metoprolol Succinate61$643
ClopidogrelClopidogrel Bisulfate62$552
Atorvastatin Calcium42$429
Losartan Potassium30$411
Isosorbide Mononitrate ErIsosorbide Mononitrate28$291
Amlodipine Besylate42$257
Hydrochlorothiazide31$224
Rosuvastatin Calcium12$213
Furosemide14$102
Carvedilol23$96
Lisinopril15$48
Prednisone12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$17,55022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →